Gadobenic acid

A contrast agent used in medical imaging

Gadobenic acid is a gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the quality of the images. It is particularly useful in imaging the liver, central nervous system, and blood vessels.

Chemical Composition

Gadobenic acid is a complex of gadolinium with a ligand known as BOPTA (benzyloxypropionic-tetraacetate). The chemical formula for gadobenic acid is C₂₂H₂₈GdN₃O₁₁. The gadolinium ion is chelated by the ligand, which helps to reduce the risk of gadolinium toxicity.

Mechanism of Action

Gadobenic acid works by altering the local magnetic field in the tissues where it accumulates. This change in the magnetic field enhances the contrast between different tissues in the MRI images. The agent is particularly effective in tissues with high blood flow or in areas with disrupted blood-brain barrier.

Clinical Uses

Gadobenic acid is used in various types of MRI scans, including:

• Liver imaging: It is used to detect and characterize liver lesions, such as hepatocellular carcinoma and metastases.
• Central nervous system imaging: It helps in identifying brain tumors, multiple sclerosis plaques, and other neurological disorders.
• Vascular imaging: It is used in magnetic resonance angiography (MRA) to visualize blood vessels and detect vascular diseases.

Safety and Side Effects

Gadobenic acid is generally well-tolerated, but like all GBCAs, it carries a risk of nephrogenic systemic fibrosis (NSF) in patients with severe kidney impairment. Common side effects include nausea, headache, and dizziness. Rarely, allergic reactions may occur.

Pharmacokinetics

After intravenous administration, gadobenic acid is distributed throughout the extracellular fluid. It is primarily excreted unchanged by the kidneys. The elimination half-life is approximately 1.5 hours in individuals with normal renal function.

Related Pages

• Gadolinium-based contrast agent
• Magnetic resonance imaging
• Nephrogenic systemic fibrosis
• Hepatocellular carcinoma